GO
Loading...

GlaxoSmithKline PLC

More

  • Biotech's Big Night Thursday, 15 May 2008 | 6:38 PM ET

    Traders will be glued to the web Thursday night as thousands of cancer studies go online. What’s the trade as these studies potentially send shock waves through biotech stocks on Friday morning?

  • Palatin Technologies: No Nose For Impotence Wednesday, 14 May 2008 | 11:45 AM ET
    Palatin Technologies

    I like to think I have a nose for news. And, some might say, too much of a penchant for puns and alliteration. Impotence drug profits won't be going up big pharma's nose. The tiny New Jersey-based biotech company Palatin Technologies says it's giving up on its experimental nasal spray for erectile dysfunction.

  • Lightning Round: Apple, Conoco, JPMorgan and More Friday, 25 Apr 2008 | 7:17 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • Amgen: Is "A" For Anemia Or Acquisition? Friday, 25 Apr 2008 | 12:35 PM ET
    AMGEN

    The morning after Amgen reported its first quarter earnings my inbox runneth over with analyst research reports on the biotech behemoth. The company beat the Street by eight cents a share. But the focus remains on the anemia drug franchise.

  • Thusday Look Ahead: Earnings to Set Course Wednesday, 23 Apr 2008 | 6:05 PM ET

    Some late day earnings news could spill into Thursday's session: Apple shares rose after the company reported a 36 percent increase in profits to $1.05 billion. But the company guided third quarter below Wall Street estimates...

  • Glaxo Buying Sirtris -- A Euro/Dollar Story Wednesday, 23 Apr 2008 | 3:34 PM ET

    GlaxoSmithKline is paying big in an effort to find cures for diseases of aging. They are buying Sirtris Pharmaceuticals for $720M in cash, or $22.50/share. This price represents an 84% premium over SIRT's closing price yesterday. Two things are going on here...

  • Schering Plows Through Vytorin Firestorm Wednesday, 23 Apr 2008 | 12:57 PM ET

    Schering-Plough beat the Street by a surprising 16 cents per share and the beaten-down shares are rallying. In an exclusive CNBC interview Wednesday morning, Chairman and CEO Fred Hassan explained how the company was able to blow away estimates...

  • Boeing's Nice Earnings vs. Weak Water IPO Wednesday, 23 Apr 2008 | 9:35 AM ET

    Futures about flat as oil is at least down a bit this morning. Earnings were mixed, and an IPO pricing was a bit disappointing. Boeing better than expected. ... How much money can an airline lose? Delta lost $6.4 billion, or $16.15 a share; its merger partner Northwest reported a net loss of $4.1 billion, or $15.78 a share...

  • GlaxoSmithKline Earnings Fall Less than Expected Wednesday, 23 Apr 2008 | 8:22 AM ET
    The company logo of GlaxoSmithKline, is seen on the headquarters building in London, Wednesday May 10, 2006. GlaxoSmithKline PLC said Wednesday it has been granted a High Court injunction against animal rights activists who sent threats to the drugmaker's shareholders, barring them from sending more letters or revealing private information about the investors. (AP Photo/Alastair Grant)

    GlaxoSmithKline’s profit fell 5 percent in the first quarter, hit by falling sales of diabetes drug Avandia and generic competition to other products, the world's second biggest drugmaker said.

  • WYE Oh Wyeth! Tuesday, 22 Apr 2008 | 7:03 PM ET

    In Tuesday’s Web Extra the traders reveal how they’re playing Pharma after Wyeth shares traded lower despite stronger-than-expected earnings. Also get the traders’ Lockheed play.

  • Europe Preview: UBS, RBS on the Hotseat Tuesday, 22 Apr 2008 | 5:36 PM ET

    Europe's two biggest casualties from the subprime crisis tomorrow face shareholders who will want answers on how, between them, the two banking giants lost well over $50 billion.

  • GlaxoSmithKline said it had agreed to buy biotechnology company Sirtris Pharmaceuticals for $720 million in cash, in hopes its medicines that modulate an aging-related family of enzymes will be effective against a wide range of diseases.

  • Halftime Report: Da Bears Are Winning Tuesday, 22 Apr 2008 | 12:41 PM ET

    This halftime report is not brought to you by (pick your prescription drug). So, we're pretty much at the midway point of big pharma's earnings season and Goldman Sachs analyst James Kelly is sizing things up so far...

  • Clank of America Monday, 21 Apr 2008 | 6:17 PM ET

    The Dow pulled back Monday after a weaker-than-expected profit report from Bank of America stirred concerns about the health of corporate earnings. What's the "Word on The Street?"

  • Springtime for Pharma: A Big Week Ahead For Earnings Friday, 18 Apr 2008 | 12:01 PM ET

    The irreverent producers of "Squawk on the Street" who are stationed in the pod next to mine here at CNBC like to call it "Pharmapalooza." They're referring to weeks like the one coming up when nearly every big drug company reports earnings.

  • Roche Misses First-Quarter Profit Forecast Thursday, 17 Apr 2008 | 12:13 PM ET
    Tamiflu Tabletten, fotografiert am Mittwoch, 15. Maerz 2006 in Frankfurt am Main. (AP Photo/Michael Probst) ---Tamiflu pills in Frankfurt, central Germany, Wednesday, March 15, 2006. (AP Photo/Michael Probst)

    Roche Holding missed forecasts with a meagre 2 percent increase in first-quarter sales in local currencies, hit by plunging Tamiflu revenue and a slowing pace of growth for cancer drugs.

  • Glaxo, Pozen Become "Headache Free" On Migraine Drug Wednesday, 16 Apr 2008 | 11:21 AM ET

    After navigating what has to be one of the most frustrating paths to Food and Drug Administration approval of a new drug, the small biopharma company Pozen and its big pharma partner GlaxoSmithKline have finally emerged victorious.

  • Genentech Earnings Preview: Cure for Portfolio Ills? Thursday, 10 Apr 2008 | 1:37 PM ET
    Genetech

    Genentech stock is on a tear this year and analysts are expecting double-digit sales growth for most of the biotech's key drugs this quarter. Can Genentech keep it up?

  • Pfizer's Viagra

    Last night while on the elliptical and watching "NBC Nightly News," one spot amid the wall-to-wall commercials for drugs caught my attention. It looks like after 10 years since the first erectile dysfunction pill came on the market--Pfizer's Viagra celebrated a decade since winning FDA approval last week--the makers of Levitra are trying a new marketing tack.

  • Panel: AIDS Drug Doubles Heart Attack Risk Tuesday, 1 Apr 2008 | 4:59 PM ET

    A drug commonly used to fight AIDS appears to nearly double the risk of a heart attack, researchers said Tuesday.